Cardiovascular Risk Management in Rheumatoid Arthritis
Summary
The management of cardiovascular risk in patients with rheumatoid arthritis (RA) demands recognition of the synergistic impact of chronic systemic inflammation and traditional risk factors on atherogenesis. RA-driven cytokine networks accelerate endothelial dysfunction, lipid derangement and plaque formation, elevating the incidence of myocardial infarction, stroke and heart failure. Risk stratification requires adaptation of standard cardiovascular risk calculators, often incorporating a multiplication factor to account for RA as a risk enhancer. Optimal prevention strategies embrace rigorous control of RA activity through disease-modifying antirheumatic drugs (DMARDs), lifestyle interventions, blood pressure and lipid management, and antiplatelet or statin therapy when indicated. Guideline frameworks recommend regular assessment of cardiovascular profiles, integration of inflammatory marker monitoring and multidisciplinary collaboration to harmonise rheumatology and cardiology care pathways. Emerging evidence underscores the necessity of early intervention and personalised regimens to mitigate long-term cardiovascular morbidity in RA.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Cardiovascular Risk Management in Rheumatoid Arthritis publication trend
The graph below shows the total number of articles in cardiovascular risk management in rheumatoid arthritis across all publications each year (not limited to Nature Index journals).
Technical terms
Rheumatoid Arthritis (RA): Chronic autoimmune disorder characterised by joint inflammation, systemic immune activation and increased cardiovascular risk.
Atherosclerosis: Pathological process involving lipid accumulation, inflammation and plaque formation within arterial walls.
Disease-modifying antirheumatic drugs (DMARDs): Agents that alter the course of RA by targeting immune pathways to reduce inflammation and prevent joint damage.
Biologic DMARDs: Protein therapeutics that selectively inhibit cytokines or cell-surface molecules implicated in RA pathogenesis.
Tumour necrosis factor inhibitors (TNFi): Biologic agents that block TNFα, a key pro-inflammatory cytokine.
Janus kinase inhibitors (JAKi): Small molecules that interfere with intracellular signalling of multiple pro-inflammatory cytokines.
Interleukin-6 inhibitors (IL-6i): Biologics targeting IL-6 to attenuate inflammation and its vascular sequelae.
Glucocorticoids: Steroidal anti-inflammatory medications used in RA for rapid symptom relief, associated with dose-dependent cardiovascular effects.
References
- Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study. Journal of Internal Medicine (2023).
- Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLOS Medicine (2020).
- Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. International Journal of Molecular Sciences (2018).
- Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatology (2018).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.